Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CytomX Therapeutics Inc.

    NASDAQ: CTMX · Real-Time Price · USD
    0.76
    0.02 (2.11%)
    At close: May 01, 2025, 3:59 PM
    0.75
    -0.75%
    After-hours: May 01, 2025, 05:41 PM EDT
    2.11%
    Bid 0.75
    Market Cap 60.53M
    Revenue (ttm) 138.1M
    Net Income (ttm) 31.87M
    EPS (ttm) 0.38
    PE Ratio (ttm) 1.99
    Forward PE -1.55
    Analyst Buy
    Ask 0.76
    Volume 678,668
    Avg. Volume (20D) 1,934,704
    Open 0.74
    Previous Close 0.74
    Day's Range 0.73 - 0.77
    52-Week Range 0.40 - 5.06
    Beta 1.33

    About CTMX

    CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Oct 8, 2015
    Employees 119
    Stock Exchange NASDAQ
    Ticker Symbol CTMX
    Website https://www.cytomx.com
    Full Company Profile

    Analyst Forecast

    According to 5 analyst ratings, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is $5.79, which is an increase of 666.18% from the latest price.

    Stock Forecasts

    Next Earnings Release

    CytomX Therapeutics Inc. is scheduled to release its earnings on May 12, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +7.71%
    CytomX Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
    5 months ago
    +9%
    CytomX Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
    news image

    1 week ago · zacks.com

    CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

    On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.

    news image

    1 month ago · zacks.com

    CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

    CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    news image

    1 month ago · zacks.com

    CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates

    CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to earnings of $0.01 per share a year a...

    news image

    1 month ago · seekingalpha.com

    CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

    CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants R...

    news image

    1 month ago · zacks.com

    CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?

    On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.

    Create Price Alert on CTMX

    Your price alert will notify you when the stock price is above 0.76.

    Add to Watchlist